Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,061,003

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,061,003
Title:Therapeutic or preventive agent for diabetes
Abstract: A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly).sub.5, Pro-Hyp, Hyp-Gly, Pro-Gly, Pro-Pro and Ala-Hyp or a chemically-modified substance thereof or a pharmaceutically acceptable salt thereof have DPPTV inhibitory activity and/or GLP-1 secretion accelerating activity, and hence are effective as a therapeutic or preventive agent or the like for diabetes.
Inventor(s): Sugihara; Fumihito (Yao, JP), Inoue; Naoki (Yao, JP), Koizumi; Seiko (Yao, JP), Yoshimoto; Tadashi (Nara, JP), Oyama; Hiroshi (Hirakata, JP)
Assignee: NITTA GELATIN INC. (Osaka, JP)
Application Number:13/981,258
Patent Claims:1. A method for treatment of diabetes comprising administering the dipeptide Pro-Ala or a pharmaceutically acceptable salt thereof to a subject in need thereof.

2. A method for inhibiting dipeptidyl peptidase IV or accelerating glucagon-like peptide-1 secretion, comprising administering the dipeptide Pro-Ala or a pharmaceutically acceptable salt thereof to a subject in need thereof.

3. The method of claim 1, further comprising administering at least one dipeptide or tripeptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Ser-Hyp and Ala-Hyp-Gly, and pharmaceutically acceptable salts thereof.

4. The method of claim 2, further comprising administering at least one dipeptide or tripeptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Ser-Hyp and Ala-Hyp-Gly, and pharmaceutically acceptable salts thereof.

5. A method for treatment of diabetes comprising administering two or more dipeptides or tripeptides selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, and pharmaceutically acceptable salts thereof to a subject in need thereof.

6. The method of claim 1, wherein the dipeptide Pro-Ala or the pharmaceutically acceptable salt thereof is administered orally or parenterally as a pharmaceutical preparation with a pharmaceutically acceptable carrier.

7. The method of claim 6, wherein the dipeptide Pro-Ala or the pharmaceutically acceptable salt thereof is present in the oral pharmaceutical preparation in a proportion of 0.001 parts by weight or more of the oral pharmaceutical preparation or in the parenteral pharmaceutical preparation in an amount of 0.1 mol/L or more in the parenteral pharmaceutical preparation.

8. The method of claim 2, wherein the dipeptide Pro-Ala or pharmaceutically acceptable salt thereof is administered orally or parenterally as a pharmaceutical preparation with a pharmaceutically acceptable carrier.

9. The method of claim 3, wherein the dipeptides or tripeptides or pharmaceutically acceptable salts thereof are administered orally or parenterally as a pharmaceutical preparation with a pharmaceutically acceptable carrier.

10. The method of claim 9, wherein the amount of dipeptides and tripeptides administered orally is about 0.1 to 1000 mg and parenterally is about 0.1 to 100 mg.

11. The method of claim 4, wherein the dipeptides or tripeptides or pharmaceutically acceptable salts thereof are administered orally or parenterally as a pharmaceutical preparation with a pharmaceutically acceptable carrier.

12. The method of claim 5, wherein the dipeptides or tripeptides or pharmaceutically acceptable salts thereof are administered orally or parenterally as a pharmaceutical preparation with a pharmaceutically acceptable carrier.

13. The method of claim 3, wherein the dipeptides and tripeptides administered are prepared by subjecting collagen or gelatin to a two-step enzymatic treatment, wherein an enzyme used in a primary enzymatic treatment is selected from the group consisting of collagenase, thiol protease, serine protease, acidic protease, alkaline protease and metal protease, and an enzyme used in a secondary enzymatic treatment is an enzyme having aminopeptidase N activity, or an enzyme having both aminopeptidase N activity and prolyl tripeptidyl aminopeptidase activity, or a combination of an enzyme having aminopeptidase N activity and an enzyme having prolyl tripeptidyl aminopeptidase activity.

14. The method of claim 5, wherein the three or more dipeptides or tripeptides and pharmaceutically acceptable salts are contained in a collagen peptide mixture, and wherein the three or more dipeptides or tripeptides and pharmaceutically acceptable salts thereof are 2% by weight or more of the collagen peptide mixture.

15. The method of claim 3, wherein a preparation containing dipeptides and tripeptides is administered to a subject in need thereof, wherein the dipeptides and tripeptides consist of Pro-Ala and one or more dipeptides or tripeptides selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, and pharmaceutically acceptable salts thereof.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2011-015095Jan 27, 2011
PCT Information
PCT FiledJanuary 25, 2012PCT Application Number:PCT/JP2012/051561
PCT Publication Date:August 02, 2012PCT Publication Number:WO2012/102308

Details for Patent 9,061,003

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial NITTA GELATIN INC. (Osaka, JP) 2031-01-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Moodys
McKesson
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.